No headlines found.
No press releases found.
No news found.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Grifols S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol GRFS.
As of February 4, 2026, GRFS stock price climbed to $9.59 with 328,972 million shares trading.
GRFS has a beta of 0.74, meaning it tends to be less sensitive to market movements. GRFS has a correlation of 0.16 to the broad based SPY ETF.
GRFS has a market cap of $6.53 billion. This is considered a Mid Cap stock.
In the last 3 years, GRFS traded as high as $12.15 and as low as $5.30.
The top ETF exchange traded funds that GRFS belongs to (by Net Assets): IBB, BINV, KOMP, SPDW, BSMC.
GRFS has outperformed the market in the last year with a price return of +47.5% while the SPY ETF gained +16.3%. GRFS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +1.7% and +11.0%, respectively, while the SPY returned +1.0% and +1.5%, respectively.
GRFS support price is $9.21 and resistance is $9.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRFS shares will trade within this expected range on the day.
